Phase 1 study of the MDM2 inhibito ... | Article | H1 Connect
[Clinical Trial: Non-RCT]
Gluck WL et al.
Investigational new drugs. 2020 06; 38(3):831-843
https://doi.org/10.1007/s10637-019-00840-1PMID: 31359240Evaluations
MDM2 plays an important role in the pathogenesis of some cancers. This study, together with {1,2}, is one of several early phase clinical trials investigating MDM2 inhibitors in various malignancies with MDM2 overexpression or amplification, showing manageable toxicity and some activity (mainly stable disease and a few partial responses) in well-differentiated liposarcoma/dedifferentiated liposarcoma.
This Recommendation is of an article referenced in a Faculty Review also written by Richard Riedel.
Relevant Specialties
Cancer Biology
Cancer TherapeuticsHematology
Lymphoid MalignanciesMolecular Medicine
Cancer TherapeuticsOncology
Cancer Therapeutics | Lymphoid Malignancies | Oncologic Drugs | SarcomasPharmacology & Drug Discovery
Cancer Therapeutics
Clinical Trials
Related Articles
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
Rosen LS et al.2007 Jun 10
Latest recommendation by:
- New Finding
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.
Voss MH et al.2019 05 01
Latest recommendation by:
- New Finding
Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.
Erlichman C et al.2006 May 20
Latest recommendation by:
- New Finding
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.
Cleary JM et al.2014 Oct
Latest recommendation by:
Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors.
Thomas A et al.2018 06 01
Latest recommendation by:
- New Finding
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
Rangwala R et al.2014 Aug
Latest recommendation by:
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
Rodrigues HV et al.2015 Jun
Latest recommendation by:
Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.
Rangwala R et al.2014 Aug
Latest recommendation by:
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Juric D et al.2019 02 01
Latest recommendation by:
- Confirmation
- Good for Teaching
- Novel Drug Target
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Infante JR et al.2012 May 01
Latest recommendation by:
- Novel Drug Target